Loading...
On May 27, 2011, the FDA approved fidaxomicin (Dificid) for the treatment of Clostridium difficile–related diarrhea in patients aged ≥18.
Mechanism of Action: Fidaxomicin, a macrocyclic antibiotic, is bactericidal and acts by inhibiting RNA synthesis. It has activity against gram-positive aerobes and anaerobes, including C. difficile. No cross-resistance with other antibiotics has been noted.
Dosage and Administration: One 200-mg tablet twice daily for 10 days, taken orally with or without food.
Pharmacokinetics, Drug Interactions, and Adverse Effects: Fidaxomicin is poorly absorbed and acts locally in the gastrointestinal tract. Dose adjustments are not necessary for organ function or age. Because the drug is not a substrate, inhibitor, or in…